RxDoctor Payments Data

Charles Salters, MD

Cardiovascular Disease · Lexington, KYNPI 1740444520

Payments from drug & device makers

$414in general payments, 2019–2025

Across 19 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$137
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
  • Novartis$56
  • Lantheus Medical Imaging, Inc.$34
  • Medtronic$30
  • Shockwave Medical, Inc$26
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$414 in reported general payments places this provider in the 15th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$106,938
Medicare patients
471
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban452$557,764
EntrestoSacubitril/Valsartan136$175,986
JardianceEmpagliflozin63$81,706
FarxigaDapagliflozin Propanediol56$75,971
XareltoRivaroxaban42$51,529
OzempicSemaglutide34$40,265
Repatha SureclickEvolocumab25$22,530
Praluent PenAlirocumab24$17,266
Ranolazine ErRanolazine99$11,546
Flecainide Acetate224$10,138
Valsartan305$7,806
Metoprolol Succinate383$5,155
Propranolol Hcl ErPropranolol Hcl94$4,719
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide236$4,622
Spironolactone490$4,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$56$175,986136 claims
Novo NordiskOzempic$20$40,26534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →